RIGEL PHARMACEUTICALS, INC. Liabilities Assumed
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Liabilities Assumed of $218.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:LiabilitiesAssumed1 · last filed 2026-08-04
- RIGEL PHARMACEUTICALS, INC. liabilities assumed for the quarter ending 2026-06-30 was -$4.78M.
- RIGEL PHARMACEUTICALS, INC. liabilities assumed for the quarter ending 2026-03-31 was $5.00M, a 0.00% change year-over-year.
- RIGEL PHARMACEUTICALS, INC. liabilities assumed for the quarter ending 2025-06-30 was $0.00.
- RIGEL PHARMACEUTICALS, INC. liabilities assumed for the quarter ending 2025-03-31 was $5.00M.
| Period end | Liabilities Assumed 3 month | Liabilities Assumed 6 month |
|---|---|---|
| 2026-06-30 | -$4.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $218.00K 10-Q · filed 2026-08-04 |
| 2026-03-31 | $5.00M 10-Q · filed 2026-05-05 | |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $5.00M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $5.00M 10-Q · filed 2026-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |